Dupixent, a biologic medication developed by Sanofi and Regeneron Pharmaceuticals, was approved by the U.S. Food and Drug Administration (FDA) in March 2017 for the treatment of moderate-to-severe atopic dermatitis [1]. Its launch marked a significant advancement in the treatment of this chronic skin condition, offering a new therapeutic option for patients who had not responded adequately to topical treatments [1].
When Did Dupixent Become Available?
Dupixent became available to patients shortly after its FDA approval in March 2017 [1]. The drug is administered via subcutaneous injection.
What Conditions Does Dupixent Treat?
Initially approved for moderate-to-severe atopic dermatitis in adults, Dupixent's indications have since expanded [1]. It is now also approved for the treatment of moderate-to-severe atopic dermatitis in children aged 6 months and older, as well as for moderate-to-severe asthma in patients aged 12 years and older whose asthma is not controlled with their current medications [2, 3]. Additional approvals include chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis [2, 3].
How Does Dupixent Work?
Dupixent targets the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) by blocking the shared receptor component, IL-4Rα [1, 2]. These cytokines are key drivers of type 2 inflammation, which plays a central role in atopic dermatitis, asthma, and other allergic and inflammatory conditions treated by Dupixent [1, 2].
What Are the Next Steps After Dupixent's Launch?
Following its initial launch, ongoing research and clinical trials have been crucial for Dupixent's expanded therapeutic reach [2, 3]. Regulatory submissions and approvals for new indications have been a key part of the drug's lifecycle, increasing its market penetration and patient access [2, 3].
What Is Dupixent's Patent and Exclusivity Status?
The patent landscape for Dupixent is complex, as is typical for biologic drugs. Information regarding specific patent expiry dates and ongoing litigation can be found on specialized resources like DrugPatentWatch.com [4]. Patent protection is critical for recouping research and development costs and for incentivizing further innovation.
How Does Dupixent Compare to Other Atopic Dermatitis Treatments?
Dupixent offers a systemic approach to treating atopic dermatitis by targeting underlying inflammation, distinguishing it from topical treatments that primarily address symptoms on the skin's surface [1]. It is a biologic therapy, differing in mechanism from traditional systemic immunosuppressants like corticosteroids or cyclosporine [1].
What are the Potential Risks and Side Effects of Dupixent?
Common side effects reported with Dupixent include injection site reactions, conjunctivitis, and oral herpes [1, 2]. More serious, though less common, side effects have also been noted in clinical trials and post-marketing surveillance [1, 2].
Who Manufactures Dupixent?
Dupixent is a product of a collaboration between Sanofi and Regeneron Pharmaceuticals [1].
---
Sources:
1. U.S. Food and Drug Administration. (2017, March 28). FDA approves Dupixent® (dupilumab) injection, the first biologic medicine for adults with moderate-to-severe atopic dermatitis. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dupixent-dupilumab-injection-questions-and-answers
2. Sanofi. (n.d.). Dupixent. Retrieved from https://www.sanofi.com/en/products-and-innovation/products-and-services/dupixent
3. Regeneron Pharmaceuticals. (n.d.). Dupixent® (dupilumab). Retrieved from https://investor.regeneron.com/products-pipeline/dupixent
4. DrugPatentWatch.com. (n.d.). Dupixent Patent Expiry. Retrieved from https://www.drugpatentwatch.com/